{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:33:57Z","timestamp":1790004837587,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":3699,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1194\/jlr.m008144","type":"journal-article","created":{"date-parts":[[2010,6,5]],"date-time":"2010-06-05T20:34:35Z","timestamp":1275770075000},"page":"2714-2721","source":"Crossref","is-referenced-by-count":226,"title":["High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol"],"prefix":"10.1016","volume":"51","author":[{"given":"Greg","family":"Welder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam","family":"Zineh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pacanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Troutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Konrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.M008144_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem. Sci."},{"key":"10.1194\/jlr.M008144_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/187153008786848286","article-title":"Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease","volume":"8","author":"Cao","year":"2008","journal-title":"Endocr. Metab. Immune Disord. Drug Targets."},{"issue":"Suppl","key":"10.1194\/jlr.M008144_bib3","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M008144_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/14728220802600715","article-title":"PCSK9 as a therapeutic target of dyslipidemia","volume":"13","author":"Seidah","year":"2009","journal-title":"Expert Opin. Ther. Targets."},{"key":"10.1194\/jlr.M008144_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tem.2006.02.001","article-title":"PCSK9: a promising therapeutic target for dyslipidemias","volume":"17","author":"Lambert","year":"2006","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1194\/jlr.M008144_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2796.2009.02167.x","article-title":"The unique role of proprotein convertase subtilisin\/kexin 9 in cholesterol homeostasis","volume":"266","author":"Mousavi","year":"2009","journal-title":"J. Intern. Med."},{"key":"10.1194\/jlr.M008144_bib7","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1194\/jlr.M008144_bib8","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1074\/jbc.M808802200","article-title":"Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells","volume":"284","author":"McNutt","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M008144_bib9","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","article-title":"Plasma PCSK9 preferentially reduces liver LDL receptors in mice","volume":"49","author":"Grefhorst","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M008144_bib10","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","article-title":"Secreted proprotein convertase subtilisin\/kexin-type 9 reduces low-density lipoprotein receptor through receptor-mediated endocytosis","volume":"48","author":"Qian","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M008144_bib11","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.M008144_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin kexin 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M008144_bib13","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.M008144_bib14","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post- endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.M008144_bib15","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M008144_bib16","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M008144_bib17","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.M008144_bib18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bbrc.2008.04.004","article-title":"Secreted proprotein convertase subtilisin\/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo","volume":"370","author":"Schmidt","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1194\/jlr.M008144_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/BJ20070664","article-title":"Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity","volume":"406","author":"Li","year":"2007","journal-title":"Biochem. J."},{"key":"10.1194\/jlr.M008144_bib20","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M008144_bib21","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M008144_bib22","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.M008144_bib23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/BJ20082407","article-title":"Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor","volume":"419","author":"Duff","year":"2009","journal-title":"Biochem. J."},{"key":"10.1194\/jlr.M008144_bib24","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1074\/jbc.M110.113035","article-title":"A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C-terminal domain antibody antigen binding fragment inhibits PCSK9 internalization and restores LDL-uptake","volume":"285","author":"Ni","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.M008144_bib25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.mol.0000162321.31925.a3","article-title":"Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia","volume":"16","author":"Maxwell","year":"2005","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.M008144_bib26","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.M008144_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1194\/jlr.M008144_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/humu.9383","article-title":"Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia","volume":"26","author":"Allard","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1194\/jlr.M008144_bib29","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1373\/clinchem.2009.129759","article-title":"Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9","volume":"55","author":"Humphries","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1194\/jlr.M008144_bib30","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.M008144_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.ATV.0000255311.26383.2f","article-title":"A novel loss-of-function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol","volume":"27","author":"Fasano","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.M008144_bib32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1194\/jlr.M008144_bib33","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.M008144_bib34","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.M008144_bib35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/01.ATV.0000204337.81286.1c","article-title":"Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy","volume":"26","author":"Berge","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.M008144_bib36","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M008144_bib37","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1373\/clinchem.2007.091280","article-title":"Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol","volume":"53","author":"Alborn","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1194\/jlr.M008144_bib38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M008144_bib39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M008144_bib40","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1592\/phco.26.11.1572","article-title":"Atorvastatin effect on circulating and leukocyte-produced CD40 ligand concentrations in people with normal cholesterol levels: a pilot study","volume":"26","author":"Zineh","year":"2006","journal-title":"Pharmacotherapy."},{"key":"10.1194\/jlr.M008144_bib41","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1592\/phco.26.12.1794","article-title":"Complementary and alternative medicine use among individuals participating in research: implications for research and practice","volume":"26","author":"Welder","year":"2006","journal-title":"Pharmacotherapy."},{"key":"10.1194\/jlr.M008144_bib42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1194\/jlr.M000620","article-title":"Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels","volume":"51","author":"Troutt","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.M008144_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis."},{"key":"10.1194\/jlr.M008144_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2010.04.015","article-title":"Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients","author":"Cariou","year":"2010","journal-title":"Atherosclerosis"}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520423016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520423016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.M008144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T18:09:47Z","timestamp":1637431787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227520423016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0022227520423016"],"URL":"https:\/\/doi.org\/10.1194\/jlr.m008144","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}